ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
87 hedge funds and large institutions have $637M invested in Adaptimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.26% less ownership
Funds ownership: 13.99% → 12.74% (-1.3%)
38% less capital invested
Capital invested by funds: $1.03B → $637M (-$393M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
87
Holding in Top 10
–
Calls
$1.23M
Puts
$767K
Top Buyers
| 1 | +$27.4M | |
| 2 | +$18.9M | |
| 3 | +$17.7M | |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$9.95M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.43M |
Top Sellers
| 1 | -$47.6M | |
| 2 | -$40.2M | |
| 3 | -$23.3M | |
| 4 |
RI
RTW Investments
New York
|
-$20.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$20.1M |